Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.

Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?

Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB.

J Int AIDS Soc. 2017 Jul 28;20(1):22146. doi: 10.7448/IAS.20.1.22146. Review.

2.

Acceptability of a microfinance-based empowerment intervention for transgender and cisgender women sex workers in Greater Kuala Lumpur, Malaysia.

Lall P, Shaw SA, Saifi R, Sherman S, Azmi NN, Pillai V, El-Bassel N, Kamarulzaman A, Wickersham JA.

J Int AIDS Soc. 2017 Aug 2;20(1):21723. doi: 10.7448/IAS.20.1.21723.

3.

Opium trade and the spread of HIV in the Golden Crescent.

Farooq SA, Rasooly MH, Abidi SH, Modjarrad K, Ali S.

Harm Reduct J. 2017 Jul 21;14(1):47. doi: 10.1186/s12954-017-0170-1. Review.

4.

Enrolment and retention of people who inject drugs in the Needle & Syringe Exchange Programme in Malaysia.

Chandrasekaran S, Kyaw NTT, Harries AD, Yee IA, Ellan P, Kurusamy T, Yusoff N, Mburu G, Mohammad WMZW, Suleiman A.

Public Health Action. 2017 Jun 21;7(2):155-160. doi: 10.5588/pha.17.0003.

5.

Integrating HIV and substance use services: a systematic review.

Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, Watt N, Balabanova D, Hogarth S, Maimaris W, Buse K, Piot P, McKee M, Perel P, Legido-Quigley H.

J Int AIDS Soc. 2017 May 30;20(1):21585. doi: 10.7448/IAS.20.1.21585.

6.

Evaluation of an online injecting drug use stigma intervention targeted at health providers in New South Wales, Australia.

Brener L, Cama E, Hull P, Treloar C.

Health Psychol Open. 2017 May 16;4(1):2055102917707180. doi: 10.1177/2055102917707180. eCollection 2017 Jan.

7.

Drug abuse-associated mortality across the lifespan: a population-based longitudinal cohort and co-relative analysis.

Kendler KS, Ohlsson H, Sundquist K, Sundquist J.

Soc Psychiatry Psychiatr Epidemiol. 2017 Jul;52(7):877-886. doi: 10.1007/s00127-017-1398-5. Epub 2017 May 26.

PMID:
28550519
8.

HIV-infected individuals who use alcohol and other drugs, and virologic suppression.

Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, Samet JH, Saitz R.

AIDS Care. 2017 Sep;29(9):1129-1136. doi: 10.1080/09540121.2017.1327646. Epub 2017 May 17.

PMID:
28513200
9.

The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.

Birger RB, Le T, Kouyos RD, Grenfell BT, Hallett TB.

PLoS One. 2017 May 11;12(5):e0177195. doi: 10.1371/journal.pone.0177195. eCollection 2017.

10.

Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia.

Bazazi AR, Wickersham JA, Wegman MP, Culbert GJ, Pillai V, Shrestha R, Al-Darraji H, Copenhaver MM, Kamarulzaman A, Altice FL.

Contemp Clin Trials. 2017 Aug;59:1-12. doi: 10.1016/j.cct.2017.05.006. Epub 2017 May 4.

PMID:
28479216
11.

Impact of illicit opioid use on T cell subsets among HIV-infected adults.

Edelman EJ, So-Armah K, Cheng DM, Doyle MF, Coleman SM, Bridden C, Gnatienko N, Lioznov DA, Blokhina E, Freiberg MS, Krupitsky EM, Emu B, Samet JH.

PLoS One. 2017 May 4;12(5):e0176617. doi: 10.1371/journal.pone.0176617. eCollection 2017.

12.

Economic study of the value of expanding HCV treatment capacity in Germany.

Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C.

BMJ Open Gastroenterol. 2017 Apr 4;4(1):e000130. doi: 10.1136/bmjgast-2016-000130. eCollection 2017.

13.

HIV, Tat and dopamine transmission.

Gaskill PJ, Miller DR, Gamble-George J, Yano H, Khoshbouei H.

Neurobiol Dis. 2017 Sep;105:51-73. doi: 10.1016/j.nbd.2017.04.015. Epub 2017 Apr 27. Review.

PMID:
28457951
14.

Violence, trauma and living with HIV: Longitudinal predictors of initiating crystal methamphetamine injection among sex workers.

Argento E, Strathdee SA, Goldenberg S, Braschel M, Montaner J, Shannon K.

Drug Alcohol Depend. 2017 Jun 1;175:198-204. doi: 10.1016/j.drugalcdep.2017.02.014. Epub 2017 Apr 19.

PMID:
28448903
15.

Evaluating network-level predictors of behavior change among injection networks enrolled in the HPTN 037 randomized controlled trial.

Smith LR, Strathdee SA, Metzger D, Latkin C.

Drug Alcohol Depend. 2017 Jun 1;175:164-170. doi: 10.1016/j.drugalcdep.2017.02.007. Epub 2017 Apr 5.

PMID:
28433895
16.

Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study.

Wiessing L, Ferri M, Běláčková V, Carrieri P, Friedman SR, Folch C, Dolan K, Galvin B, Vickerman P, Lazarus JV, Mravčík V, Kretzschmar M, Sypsa V, Sarasa-Renedo A, Uusküla A, Paraskevis D, Mendão L, Rossi D, van Gelder N, Mitcheson L, Paoli L, Gomez CD, Milhet M, Dascalu N, Knight J, Hay G, Kalamara E, Simon R; EUBEST working group, Comiskey C, Rossi C, Griffiths P.

Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6.

17.

A Systematic Review and Meta-analysis of Psychosocial Interventions to Reduce Drug and Sexual Blood Borne Virus Risk Behaviours Among People Who Inject Drugs.

Gilchrist G, Swan D, Widyaratna K, Marquez-Arrico JE, Hughes E, Mdege ND, Martyn-St James M, Tirado-Munoz J.

AIDS Behav. 2017 Jul;21(7):1791-1811. doi: 10.1007/s10461-017-1755-0. Review.

18.

The material, moral, and affective worlds of dealing and crime among young men entrenched in an inner city drug scene.

Fast D, Shoveller J, Kerr T.

Int J Drug Policy. 2017 Jun;44:1-11. doi: 10.1016/j.drugpo.2017.01.003. Epub 2017 Mar 23.

PMID:
28343062
19.

Multidrug resistant tuberculosis in prisons located in former Soviet countries: A systematic review.

Droznin M, Johnson A, Johnson AM.

PLoS One. 2017 Mar 23;12(3):e0174373. doi: 10.1371/journal.pone.0174373. eCollection 2017. Review.

20.

The acceptability and feasibility of a brief psychosocial intervention to reduce blood-borne virus risk behaviours among people who inject drugs: a randomised control feasibility trial of a psychosocial intervention (the PROTECT study) versus treatment as usual.

Gilchrist G, Swan D, Shaw A, Keding A, Towers S, Craine N, Munro A, Hughes E, Parrott S, Strang J, Taylor A, Watson J.

Harm Reduct J. 2017 Mar 21;14(1):14. doi: 10.1186/s12954-017-0142-5.

Supplemental Content

Support Center